Literature DB >> 35984590

Cannabinoid Type 1 Receptors in the Basolateral Amygdala Regulate ACPA-Induced Place Preference and Anxiolytic-Like Behaviors.

Tomohiro Tokutake1, Takashi Asano1, Hajime Miyanishi1, Shigetoshi Nakaya1, Naotaka Izuo1, Atsumi Nitta2.   

Abstract

The number of cannabis users is increasing in the world. However, the mechanisms involved in the psychiatric effects and addiction formation remain unclear. Medical treatments against cannabis addiction have not yet been established. Δ9-Tetrahydrocannabinol (THC), the main active substance in cannabis, binds and affects cannabinoid type 1 receptors (CB1R) in the brain. The mice were intraperitoneally (i.p.) administered arachidonylcyclopropylamide (ACPA), a CB1R-selective agonist, and then two behavioral experiments on anxiety and addiction were performed. Administration of ACPA caused anxiolytic-like behavior in the elevated plus maze test. In addition, ACPA increased place preference in a conditioned place preference (CPP) test. The basolateral amygdala (BLA), which is the focus of this study, is involved in anxiety-like behavior and reward and is reported to express high levels of CB1R. We aimed to reveal the role of CB1R in BLA for ACPA-induced behavior. AM251, a CB1R selective antagonist, was administered intra-BLA before i.p. administration of ACPA. Intra-BLA administration of AM251 inhibited ACPA-induced anxiolytic-like behavior and place preference. These results suggest that CB1R in the BLA contributes to behavior disorders caused by the acute or chronic use of cannabis.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  ACPA; AM251; Anxiety; Basolateral amygdala; CB1R; Cannabis addiction

Mesh:

Substances:

Year:  2022        PMID: 35984590     DOI: 10.1007/s11064-022-03708-8

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   4.414


  59 in total

1.  Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study.

Authors:  Stanley Zammit; Peter Allebeck; Sven Andreasson; Ingvar Lundberg; Glyn Lewis
Journal:  BMJ       Date:  2002-11-23

Review 2.  Cannabinoids for Medical Use: A Systematic Review and Meta-analysis.

Authors:  Penny F Whiting; Robert F Wolff; Sohan Deshpande; Marcello Di Nisio; Steven Duffy; Adrian V Hernandez; J Christiaan Keurentjes; Shona Lang; Kate Misso; Steve Ryder; Simone Schmidlkofer; Marie Westwood; Jos Kleijnen
Journal:  JAMA       Date:  2015 Jun 23-30       Impact factor: 56.272

3.  Structure of a cannabinoid receptor and functional expression of the cloned cDNA.

Authors:  L A Matsuda; S J Lolait; M J Brownstein; A C Young; T I Bonner
Journal:  Nature       Date:  1990-08-09       Impact factor: 49.962

Review 4.  Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology.

Authors:  Barbara S Koppel; John C M Brust; Terry Fife; Jeff Bronstein; Sarah Youssof; Gary Gronseth; David Gloss
Journal:  Neurology       Date:  2014-04-29       Impact factor: 9.910

Review 5.  Cannabinoid signalling.

Authors:  Dirk G Demuth; Areles Molleman
Journal:  Life Sci       Date:  2005-08-18       Impact factor: 5.037

Review 6.  Positive and Negative Effects of Cannabis and Cannabinoids on Health.

Authors:  Koby Cohen; Abraham Weizman; Aviv Weinstein
Journal:  Clin Pharmacol Ther       Date:  2019-03-12       Impact factor: 6.875

Review 7.  Cannabis use and mania symptoms: a systematic review and meta-analysis.

Authors:  Melanie Gibbs; Catherine Winsper; Steven Marwaha; Eleanor Gilbert; Matthew Broome; Swaran P Singh
Journal:  J Affect Disord       Date:  2014-09-23       Impact factor: 4.839

Review 8.  Cannabis use and first manic episode.

Authors:  Nathalie Bally; Daniele Zullino; Jean-Michel Aubry
Journal:  J Affect Disord       Date:  2014-04-24       Impact factor: 4.839

Review 9.  Safety and Toxicology of Cannabinoids.

Authors:  Jane Sachs; Erin McGlade; Deborah Yurgelun-Todd
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

Review 10.  Cannabis Addiction and the Brain: a Review.

Authors:  Amna Zehra; Jamie Burns; Christopher Kure Liu; Peter Manza; Corinde E Wiers; Nora D Volkow; Gene-Jack Wang
Journal:  J Neuroimmune Pharmacol       Date:  2018-03-19       Impact factor: 4.147

View more
  1 in total

1.  Shati/Nat8l Overexpression Improves Cognitive Decline by Upregulating Neuronal Trophic Factor in Alzheimer's Disease Model Mice.

Authors:  Kakeru Chino; Naotaka Izuo; Hiroshi Noike; Kyosuke Uno; Tomoharu Kuboyama; Chihiro Tohda; Shin-Ichi Muramatsu; Atsumi Nitta
Journal:  Neurochem Res       Date:  2022-06-27       Impact factor: 4.414

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.